References
- Balch, C.M., Buzaid, A.C., Soong, S.J., Atkins, M.B., Cascinelli, N., Coit, D.G., Fleming, I.D., Gershenwald, J.E., Houghton, A., Jr., Kirkwood, J.M., McMasters, K.M., Mihm, M.F., Morton, D.L., Reintgen, D.S., Ross, M.I., Sober, A., Thompson, J.A., Thompson. J.F. (2001). Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J. Clin. Oncol., 19(16), 3635-3648.
- Bittner, M., Meltzer, P., Chen, Y., Jiang, Y., Seftor, E., Hendrix, M., Radmacher, M., Simon, R., Yakhini, Z., Ben-Dor, A., Sampas, N., Dougherty, E., Wang, E., Marincola, F., Gooden, C., Lueders, J., Glatfelter, A., Pollock, P., Carpten, J., Gillanders, E., Leja, D., Dietrich, K., Beaudry, C., Berens, M., Alberts, D., Sondak, V. (2000). Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature, 406(6795), 536-540.
- Blackwood, M. A., Holmes, R., Synnestvedt, M., Young, M., George, C., Yang, H., Elder D. E., Schuchter, L. M., Guerry, D., Ganguly, A. (2002). Multiple primary melanoma revisited. Cancer., 94(8), 2248-2255.
- Byrd, K.M., Wilson, D.C., Hoyler, S.S., Peck, G.L. (2004). Advanced presentation of melanoma in African Americans. J. Amer. Acad. Dermatol., 50(1), 142-143.
- Clark, W.H. Jr., Elder, D.E., Guerry, D. 4th, Epstein, M.N., Greene, M.H., Van Horn, M. (1984). A study of tumor progression: The precursor lesions of superficial spreading and nodular melanoma. Hum. Pathol., 15(12), 1147-1165.
- Curtin, J.A., Fridlyand, J., Kageshita, T., Patel, H.N., Busam, K.J., Kutzner, H., Cho, K.H., Aiba, S., Brocker, E.B., LeBoit, P.E., Pinkel, D., Bastian, B.C. (2005). Distinct sets of genetic alterations in melanoma. New Engl. J. Med., 353(20), 2135-2147.
- Danen, E.H., Ten Berge, P.J., Van Muijen, G.N., Van't Hof-Grootenboer, A.E., Brocker, E.B., Ruiter, D.J. (1994). Emergence of alpha 5 beta 1 fibronectin- and alpha v beta 3 vitronectin-receptor expression in melanocytic tumour progression. Histopathology, 24(3), 249-256.
- Daniotti, M., Oggionni, M., Ranzani, T., Vallacchi, V., Campi, V., Di Stasi, D., Torre, G.D., Perrone, F., Luoni, C., Suardi, S., Frattini, M., Pilotti, S., Anichini, A., Tragni, G., Parmiani, G., Pierotti, M.A., Rodolfo, M. (2004). BRAF alterations are associated with complex mutational profiles in malignant melanoma. Oncogene, 23(35), 5968-5977.
- Davies, H., Bignell, G.R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M.J., Bottomley, W., Davis, N., Dicks, E., Ewing, R., Floyd, Y., Gray, K., Hall, S., Hawes, R., Hughes, J., Kosmidou, V., Menzies, A., Mould, C., Parker, A., Stevens, C., Watt, S., Hooper, S., Wilson, R., Jayatilake, H., Gusterson, B.A., Cooper, C., Shipley, J., Hargrave, D., Pritchard-Jones, K., Maitland, N., Chenevix-Trench, G., Riggins, G.J., Bigner, D.D., Palmieri, G., Cossu, A., Flanagan, A., Nicholson, A., Ho, J.W., Leung, S.Y., Yuen, S.T., Weber, B.L., Seigler, H.F., Darrow, T.L., Paterson, H., Marais, R., Marshall, C.J., Wooster, R., Stratton, M.R., Futreal, P.A. (2002). Mutations of the BRAF gene in human cancer. Nature, 417(6892), 949-954.
- de Snoo, F.A., Hayward, N.K. (2005). Cutaneous melanoma susceptibility and progression genes. Cancer Lett., 230(2), 153-186.
- Demunter, A., Stas, M., Degreef, H., De Wolf-Peeters, C., van den Oord, J.J. (2001). Analysis of N- and K-ras mutations in the distinctive tumor progression phases of melanoma. J. Invest. Dermatol., 117(6), 1483-1489.
- Dhawan, P., Singh, A.B., Ellis, D.L., Richmond, A. (2002). Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-kappaB and tumor progression. Cancer Res., 62(24), 7335-7342.
- Diepgen, T.L., Mahler, V. (2002). The epidemiology of skin cancer. Brit. J. Dermatol., 146 (Suppl. 61), 1-6.
- Du, J., Miller, A.J., Widlund, H.R., Horstmann, M.A., Ramaswamy, S., Fisher, D.E. (2003). MLANA/MART1 and SILV/PMEL17/GP100 are transcriptionally regulated by MITF in melanocytes and melanoma. Amer. J. Pathol., 163(1), 333-343.
- Duncan, L.M., Deeds, J., Cronin, F.E., Donovan, M., Sober, A.J., Kauffman, M., McCarthy, J.J. (2001). Melastatin expression and prognosis in cutaneous malignant melanoma. J. Clin. Oncol., 19(2), 568-576.
- Edwards, R.H., Ward, M.R., Wu, H., Medina, C.A., Brose, M.S., Volpe, P., Nussen-Lee, S., Haupt, H.M., Martin, A.M., Herlyn, M., Lessin, S.R., Weber, B.L. (2004). Absence of BRAF mutations in UV-protected mucosal melanomas. J. Med. Genet., 41(4), 270-272.
- Felding-Habermann, B., Fransvea, E., O'Toole, T.E., Manzuk, L., Faha, B., Hensler, M. (2002). Involvement of tumor cell integrin alpha v beta 3 in hematogenous metastasis of human melanoma cells. Clin. Exp. Metastasis, 19(5), 427-436.
- Garbe, C., McLeod, G.R., Buettner, P.G. (2000). Time trends of cutaneous melanoma in Queensland, Australia and Central Europe. Cancer, 89, 1269-1278.
- Garraway, L.A., Widlund, H.R., Rubin, M.A., Getz, G., Berger, A.J., Ramaswamy, S., Beroukhim, R., Milner, D.A., Granter, S.R., Du, J., Lee, C., Wagner, S.N., Li, C., Golub, T.R., Rimm, D.L., Meyerson, M.L., Fisher, D.E., Sellers, W.R. (2005). Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature, 436(7047), 117-122.
- Goldstein, A.M., Chan, M., Harland, M., Hayward, N.K., Demenais, F., Timothy Bishop, D., Azizi, E., Bergman, W., Bianchi-Scarra, G., Bruno, W., Calista, D., Cannon Albright, L.A., Chaudru, V., Chompret, A., Cuellar, F., Elder, D.E., Ghiorzo, P., Gillanders, E.M., Gruis, N.A., Hansson, J., Hogg, D., Holland, E.A., Kanetsky, P.A., Kefford, R.F., Teresa Landi, M., Lang, J., Leachman, S.A., Mackie, R.M., Magnusson, V., Mann, G.J., Newton Bishop, J., Palmer, J.M., Puig, S., Puig-Butille, J.A., Stark, M., Tsao, H., Tucker, M.A., Whitaker, L., Yakobson, E. (2007). Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J. Med. Genet., 44(2), 99-106.
- Gorden, A., Osman, I., Gai, W., He, D., Huang, W., Davidson, A., Houghton, A.N., Busam, K., Polsky, D. (2003). Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Res., 63(14), 3955-3957.
- Gray-Schopfer, V.C., Cheong, S.C., Chong, H., Chow, J., Moss, T., Abdel-Malek, Z.A., Marais, R., Wynford-Thomas, D., Bennett, D.C. (2006). Cellular senescence in naevi and immortalisation in melanoma: A role for p16? Br. J. Cancer, 95(4), 496-505.
- Hammock, L., Cohen, C., Carlson, G., Murray, D., Ross, J.S., Sheehan, C., Nazir, T.M., Carlson, J.A. (2006). Chromogenic in situ hybridization analysis of melastatin mRNA expression in melanomas from American Joint Committee on Cancer stage I and II patients with recurrent melanoma. J. Cutan. Pathol., 33(9), 599-607.
- Haqq, C., Nosrati, M., Sudilovsky, D., Crothers, J., Khodabakhsh, D., Pulliam, B.L., Federman, S., Miller, J.R. 3rd, Allen, R.E., Singer, M.I., Leong, S.P., Ljung, B.M., Sagebiel, R.W., Kashani-Sabet, M. (2005). The gene expression signatures of melanoma progression. Proc. Natl. Acad. Sci. USA, 102(17), 6092-6097.
- Hofmann, U.B., Westphal, J.R., Waas, E.T., Becker, J.C., Ruiter, D.J., van Muijen, G.N. (2000) Coexpression of integrin alpha(v)beta3 and matrix metalloproteinase-2 (MMP-2) coincides with MMP-2 activation: correlation with melanoma progression. J. Invest. Dermatol., 115(4), 625-632.
- Hornberg, J.J., Bruggeman, F.J., Westerhoff, H.V., Lankelma, J. (2006). Cancer: A Systems Biology disease. Biosystems, 83(2-3), 81-90.
- Hsu, M.Y., Meier, F.E., Nesbit, M., Hsu, J.Y., Van Belle, P., Elder, D.E., Herlyn, M. (2000a). E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors. Amer. J. Pathol., 156(5), 1515-1525.
- Hsu, M., Andl, T., Li, G., Meinkoth, J.L., Herlyn, M. (2000b). Cadherin repertoire determines partner-specific gap junctional communication during melanoma progression. J. Cell Sci., 113 (Pt 9), 1535-1542.
- Jiveskog, S., Ragnarsson-Olding, B., Platz, A., Ringborg, U. (1998). N-ras mutations are common in melanomas from sun-exposed skin of humans but rare in mucosal membranes or unexposed skin. J. Invest. Dermatol., 111(5), 757-761.
- Kumar, R., Angelini, S., Snellman, E., Hemminki, K. (2004). BRAF mutations are common somatic events in melanocytic nevi. J. Invest. Dermatol., 122(2), 342-348.
- Li, X., Regezi, J., Ross, F.P., Blystone, S., Ilic, D., Leong, S.P., Ramos, D.M. (2001). Integrin alphavbeta3 mediates K1735 murine melanoma cell motility in vivo and in vitro. J. Cell Sci., 114(Pt 14), 2665-2672.
- Liaw, D., Marsh, D.J., Li, J., Dahia, P.L., Wang, S.I., Zheng, Z., Bose, S., Call, K.M., Tsou, H.C., Peacocke, M., Eng, C., Parsons, R. (1997). Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat. Genet., 16(1), 64-67.
- Miller, A.J., Mihm, M.C. Jr. (2006). Melanoma. New Engl. J. Med., 355(1), 51-65.
- Ortega, S., Malumbres, M., Barbacid, M. (2002). Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta, 1602(1), 73-87.
- Papp, T., Pemsel, H., Zimmermann, R., Bastrop, R., Weiss, D.G., Schiffmann, D. (1999). Mutational analysis of the N-ras, p53, p16INK4a, CDK4, and MC1R genes in human congenital melanocytic naevi. J. Med. Genet., 36(8), 610-614.
- Petitelerc, E., Stromblad, S., von Schalscha, T.L., Mitjans, F., Piulats, J., Montgomery, A.M., Cheresh, D.A., Brooks, P.C. (1999). Integrin alpha(v)beta3 promotes M21 melanoma growth in human skin by regulating tumor cell survival. Cancer Res., 59(11), 2724-2730.
- Pollock, P.M., Harper, U.L., Hansen, K.S., Yudt, L.M., Stark, M., Robbins, C.M., Moses, T.Y., Hostetter, G., Wagner, U., Kakareka, J., Salem, G., Pohida, T., Heenan, P., Duray, P., Kallioniemi, O., Hayward, N.K., Trent, J.M., Meltzer, P.S. (2003). High frequency of BRAF mutations in nevi. Nat. Genet., 33(1), 19-20.
- Poynter, J.N., Elder, J.T., Fullen, D.R., Nair, R.P., Soengas, M.S., Johnson, T.M., Redman, B., Thomas, N.E., Gruber, S.B. (2006). BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res., 16(4), 267-273.
- Reifenberger, J., Knobbe, C.B., Sterzinger, A.A., Blaschke, B., Schulte, K.W., Ruzicka, T., Reifenberger, G. (2004). Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas. Int. J. Cancer, 109(3), 377-384.
- Rhodes, A.R., Weinstock, M.A., Fitzpatrick, T.B., et al. (1987). Risk factors for cutaneous melanoma. A practical method of recognizing predisposed individuals. JAMA, 258(21), 3146-3154.
- Rodolfo, M., Daniotti, M., Vallacchi, V. (2004). Genetic progression of metastatic melanoma. Cancer Lett., 214(2), 133-147.
- Rusciano, D. (2000). Differentiation and metastasis in melanoma. Crit. Rev. Oncog., 11(2), 147-163.
- Saldanha, G., Purnell, D., Fletcher, A., Potter, L., Gillies, A., Pringle, J.H. (2004). High BRAF mutation frequency does not characterize all melanocytic tumor types. Int. J. Cancer, 111(5), 705-710.
- Sasaki, Y., Niu, C., Makino, R., Kudo, C., Sun, C., Watanabe, H., Matsunaga, J., Takahashi, K., Tagami, H., Aiba, S., Horii, A. (2004). BRAF point mutations in primary melanoma show different prevalences by subtype. J. Invest. Dermatol., 123(1), 177-183.
- Sharpless, N.E., DePinho, R.A. (2005). Cancer: Crime and punishment. Nature, 436(7051), 636-637.
- Stahl, J.M., Sharma, A., Cheung, M., Zimmerman, M., Cheng, J.Q., Bosenberg, M.W., Kester, M., Sandirasegarane, L., Robertson, G.P. (2004). Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res., 64(19), 7002-7010.
- Takeuchi, H., Kuo, C., Morton, D.L., Wang, H.J., Hoon, D.S. (2003). Expression of differentiation melanoma-associated antigen genes is associated with favorable disease outcome in advanced-stage melanomas. Cancer Res., 63(2), 441-448.
- Thomas, N.E., Alexander, A., Edmiston, S.N., Parrish, E., Millikan, R.C., Berwick, M., Groben, P., Ollila, D.W., Mattingly, D., Conway, K. (2004). Tandem BRAF mutations in primary invasive melanomas. J. Invest. Dermatol., 122(5), 1245-1250.
- Tsao, H., Goel, V., Wu, H., Yang, G., Haluska, F.G. (2004). Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J. Invest. Dermatol., 122(2), 337-341.
- Tsao, H., Zhang, X., Fowlkes, K., Haluska, F.G. (2000). Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. Cancer Res., 60(7), 1800-1804.
- Uribe, P., Wistuba, I.I., Gonzalez, S. (2003). BRAF mutation: a frequent event in benign, atypical, and malignant melanocytic lesions of the skin. Amer. J. Dermatopathol., 25(5), 365-670.
- van Elsas, A., Zerp, S.F., van der Flier, S., Kruse, K.M., Aarnoudse, C., Hayward, N.K., Ruiter, D.J., Schrier, P.I. (1996). Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma. Amer. J. Pathol., 149(3), 883-893.
- Williams, M.L., Sagebiel, R.W. (1994). Melanoma risk factors and atypical moles. West. J. Med., 160(4), 343-350.
- Wu, H., Goel, V., Haluska, F.G. (2003). PTEN signaling pathways in melanoma. Oncogene, 22(20), 3113-3122.
- Yazdi, A.S., Palmedo, G., Flaig, M.J., Puchta, U., Reckwerth, A., Rutten, A., Mentzel, T., Hugel, H., Hantschke, M., Schmid-Wendtner, M.H., Kutzner, H., Sander, C.A. (2003). Mutations of the BRAF gene in benign and malignant melanocytic lesions. J. Invest. Dermatol., 121(5), 1160-1162.
- Zhang, Y., Xiong, Y., Yarbrough, W.G. (1998). ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell, 92(6), 725-734.